Proton pump inhibitors for eosinophilic oesophagitis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To review the significance and plausible mechanisms underlying 'proton pump inhibitor (PPI) responsive oesophageal eosinophilia' in eosinophilic oesophagitis (EoE). RECENT FINDINGS: EoE is defined as an immune-mediated clinicopathologic condition characterized by oesophageal dysfunction and eosinophil-predominant inflammation. This new conceptual definition has been proposed partly due to a recently identified disease phenotype called 'PPI-responsive oesophageal eosinophilia'. Emerging data support the possibility that this condition represents a clinical response to anti-inflammatory properties of PPIs that are independent of effects on gastric acid. SUMMARY: Currently, the diagnosis of EoE is reserved for patients with oesophageal eosinophilia and symptoms that do not respond to PPIs. This practice may not be appropriate, however, both because gastric acid suppression by PPIs might benefit EoE patients and because PPIs have anti-inflammatory properties that also might benefit EoE patients. More studies are sorely needed to understand the mechanisms underlying PPI-responsive oesophageal eosinophilia. Currently, a favourable response to PPI therapy should not be regarded as a proof of an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it preclude a diagnosis of EoE. Furthermore, it seems prudent to recommend a trial of PPI therapy for patients with oesophageal eosinophilia and symptoms, even when the diagnosis of EoE seems clear-cut.

Original languageEnglish (US)
Pages (from-to)416-420
Number of pages5
JournalCurrent Opinion in Gastroenterology
Volume29
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

Eosinophilic Esophagitis
Proton Pump Inhibitors
Eosinophilia
Gastric Acid
Anti-Inflammatory Agents
Gastroesophageal Reflux
Eosinophils
Digestion
Inflammation
Phenotype
Acids
Therapeutics

Keywords

  • eosinophilic oesophagitis
  • gastroesophageal reflux disease
  • proton pump inhibitors

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Proton pump inhibitors for eosinophilic oesophagitis. / Cheng, Edaire.

In: Current Opinion in Gastroenterology, Vol. 29, No. 4, 07.2013, p. 416-420.

Research output: Contribution to journalArticle

@article{7b5e48341e37483b974d974b1c61d811,
title = "Proton pump inhibitors for eosinophilic oesophagitis",
abstract = "PURPOSE OF REVIEW: To review the significance and plausible mechanisms underlying 'proton pump inhibitor (PPI) responsive oesophageal eosinophilia' in eosinophilic oesophagitis (EoE). RECENT FINDINGS: EoE is defined as an immune-mediated clinicopathologic condition characterized by oesophageal dysfunction and eosinophil-predominant inflammation. This new conceptual definition has been proposed partly due to a recently identified disease phenotype called 'PPI-responsive oesophageal eosinophilia'. Emerging data support the possibility that this condition represents a clinical response to anti-inflammatory properties of PPIs that are independent of effects on gastric acid. SUMMARY: Currently, the diagnosis of EoE is reserved for patients with oesophageal eosinophilia and symptoms that do not respond to PPIs. This practice may not be appropriate, however, both because gastric acid suppression by PPIs might benefit EoE patients and because PPIs have anti-inflammatory properties that also might benefit EoE patients. More studies are sorely needed to understand the mechanisms underlying PPI-responsive oesophageal eosinophilia. Currently, a favourable response to PPI therapy should not be regarded as a proof of an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it preclude a diagnosis of EoE. Furthermore, it seems prudent to recommend a trial of PPI therapy for patients with oesophageal eosinophilia and symptoms, even when the diagnosis of EoE seems clear-cut.",
keywords = "eosinophilic oesophagitis, gastroesophageal reflux disease, proton pump inhibitors",
author = "Edaire Cheng",
year = "2013",
month = "7",
doi = "10.1097/MOG.0b013e32835fb50e",
language = "English (US)",
volume = "29",
pages = "416--420",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Proton pump inhibitors for eosinophilic oesophagitis

AU - Cheng, Edaire

PY - 2013/7

Y1 - 2013/7

N2 - PURPOSE OF REVIEW: To review the significance and plausible mechanisms underlying 'proton pump inhibitor (PPI) responsive oesophageal eosinophilia' in eosinophilic oesophagitis (EoE). RECENT FINDINGS: EoE is defined as an immune-mediated clinicopathologic condition characterized by oesophageal dysfunction and eosinophil-predominant inflammation. This new conceptual definition has been proposed partly due to a recently identified disease phenotype called 'PPI-responsive oesophageal eosinophilia'. Emerging data support the possibility that this condition represents a clinical response to anti-inflammatory properties of PPIs that are independent of effects on gastric acid. SUMMARY: Currently, the diagnosis of EoE is reserved for patients with oesophageal eosinophilia and symptoms that do not respond to PPIs. This practice may not be appropriate, however, both because gastric acid suppression by PPIs might benefit EoE patients and because PPIs have anti-inflammatory properties that also might benefit EoE patients. More studies are sorely needed to understand the mechanisms underlying PPI-responsive oesophageal eosinophilia. Currently, a favourable response to PPI therapy should not be regarded as a proof of an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it preclude a diagnosis of EoE. Furthermore, it seems prudent to recommend a trial of PPI therapy for patients with oesophageal eosinophilia and symptoms, even when the diagnosis of EoE seems clear-cut.

AB - PURPOSE OF REVIEW: To review the significance and plausible mechanisms underlying 'proton pump inhibitor (PPI) responsive oesophageal eosinophilia' in eosinophilic oesophagitis (EoE). RECENT FINDINGS: EoE is defined as an immune-mediated clinicopathologic condition characterized by oesophageal dysfunction and eosinophil-predominant inflammation. This new conceptual definition has been proposed partly due to a recently identified disease phenotype called 'PPI-responsive oesophageal eosinophilia'. Emerging data support the possibility that this condition represents a clinical response to anti-inflammatory properties of PPIs that are independent of effects on gastric acid. SUMMARY: Currently, the diagnosis of EoE is reserved for patients with oesophageal eosinophilia and symptoms that do not respond to PPIs. This practice may not be appropriate, however, both because gastric acid suppression by PPIs might benefit EoE patients and because PPIs have anti-inflammatory properties that also might benefit EoE patients. More studies are sorely needed to understand the mechanisms underlying PPI-responsive oesophageal eosinophilia. Currently, a favourable response to PPI therapy should not be regarded as a proof of an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it preclude a diagnosis of EoE. Furthermore, it seems prudent to recommend a trial of PPI therapy for patients with oesophageal eosinophilia and symptoms, even when the diagnosis of EoE seems clear-cut.

KW - eosinophilic oesophagitis

KW - gastroesophageal reflux disease

KW - proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84879972931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879972931&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e32835fb50e

DO - 10.1097/MOG.0b013e32835fb50e

M3 - Article

C2 - 23449027

AN - SCOPUS:84879972931

VL - 29

SP - 416

EP - 420

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -